Browsing Centre for Biochemical Pharmacology by Author "Gilroy, DW"
Now showing items 1-4 of 4
-
15-epi-lipoxin A(4)-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation
Paul-Clark, MJ; van Cao, T; Moradi-Bidhendi, N; Cooper, D; Gilroy, DW (2004-07-05) -
Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease.
China, L; Maini, A; Skene, SS; Shabir, Z; Sylvestre, Y; Colas, RA; Ly, L; Becares Salles, N; Belloti, V; Dalli, J (2018-05)BACKGROUND & AIMS: Patients with acute decompensation and acute-on-chronic liver failure (AD/ACLF) have immune dysfunction, which increases their risk for infections; however, there are no effective treatments to restore ... -
Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.
Motwani, MP; Colas, RA; George, MJ; Flint, JD; Dalli, J; Richard-Loendt, A; De Maeyer, RP; Serhan, CN; Gilroy, DW (2018-03-22)While the treatment of inflammatory disorders is generally based on inhibiting factors that drive onset of inflammation, these therapies can compromise healing (NSAIDs) or dampen immunity against infections (biologics). ... -
Prolonged immune alteration following resolution of acute inflammation in humans.
Motwani, MP; Newson, J; Kwong, S; Richard-Loendt, A; Colas, R; Dalli, J; Gilroy, DW (2017)Acute inflammation is an immediate response to infection and injury characterised by the influx of granulocytes followed by phagocytosing mononuclear phagocytes. Provided the antigen is cleared and the immune system of the ...